A translational approach to ventilator associated pneumonia

Ornella Piazza and Xiangdong Wang

Abstract

The management of Ventilator Associated Pneumonia (VAP) presents many difficulties because of the heterogeneity of the disease; the way the immunocompromised host and the aggressive ICU environment interact is only partially discovered, the available biomarkers for diagnosis are not sufficient to ensure prompt differentiation between sick patients and patients at risk, the microbiological cultures require invasive techniques and time consuming methods. A translational medicine and bio-informatics approach can enable the identification of the main players of pathology, which may represent novel therapeutic targets or biomarker candidates. Analysis of proteome i.e. allows to individuate proteins that act as biomarkers, for patient-centered research strategies. Similarly, the genomic approach has proved useful to individuate those patients who are prone to develop VAP, and, in the future, we could be able to immunomodulate their responses to save them from nosocomial infections.

Keywords: VAP; Tracheobronchitis; Biomarkers; sTREM; Procalcitonin

Introduction

VAP (Ventilator Associated Pneumonia) is classically defined as a hospital-acquired pneumonia developing 48 hours or later after the beginning of mechanical ventilation.

Since VAP diagnosis founded on radiographic findings of pneumonia, which have intrinsic variability in technique, interpretation, and reporting, and on clinical signs and symptoms that are subjective- in 2011 a Working Group of the CDC (Centers for Disease Control and Prevention) proposed a new approach to surveillance for Ventilator-Associated Events (VAE). According to the new CDC definition algorithm, VAP is an Infection-related Ventilator-Associated Complication (IVAC) occurring after 3 days of mechanical ventilation and 2 days before or after the onset of worsening oxygenation, if purulent respiratory secretions with positive cultures or objective signs of respiratory infection have been found [1]. The need for a new and efficacious operative definition is comprehensible, since VAP remains one of the commonest nosocomial infections in the intensive care unit (ICU), affecting 8% to 28% of patients receiving mechanical ventilation [2]. Patients who develop a VAP have significantly more ventilator days, hospital days, and antibiotic days and higher hospital mortality than patients who have not this condition. The hazard for mortality is calculated about 7.2 (95% CI 5.1 - 10.3) for VAP identified by prospective surveillance [3]. Thanks to the generic improvements in critical care [4], mortality following VAP decreased slightly over time. Even if the “ventilator bundle” (4 items to prevent respiratory complications: stress ulcer prophylaxis, deep venous thrombosis prophylaxis, head-of-bed elevation, daily sedation vacation with weaning assessment), introduced by the Institute for Health Care Improvement, has been partially accepted, there is little evidence of its efficacy up to now [5] and no specific intervention has been yet individuated to eradicate VAP. Over the past decade, the accuracy of initial antibiotic treatment has been manifest as one of the most consistent prognostic factor: early aggressive therapy with adequate broad-spectrum regimens against the likely pathogens is associated with lower mortality rates and shorter length of hospital stay (LOS). Patients receiving inadequate antibiotic therapy compared with patients receiving adequate antibiotic therapy reported a significantly longer hospital LOS: this was calculated as plus 16.4 days (p = 0.009) for VAP [6]. There is general agreement that the causative agent

© 2014 Piazza and Wang; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
should be identified at the onset and intensely treated in order to achieve long-lasting remission but prompt diagnosis and individuation of pathogens are still difficult. Diagnostic methods with good sensitivity already exist for VAP: they are the simple clinical criteria, but a biomarker with high specificity it is needed to guide the clinician towards the sources of infection: increasing the specificity of any screening test, the fewer false positive would reduce the cost of antibiotics and invasive diagnostic strategies.

While its is clear the importance of a rapid causative diagnosis, it remains unknown why some intubated patients remain infection free while other develop VAP and other tracheobronchitis [7]. Ventilator-associated tracheobronchitis (VAT) is very common in intubated critically ill patients. This infection represents an intermediate process between colonization of lower respiratory tract and VAT. VAT is characterized by increased purulent sputum production and lower respiratory tract inflammation resulting in difficult weaning and prolonged duration of mechanical ventilation.

This area of controversy about the interaction between the patient and his/her intensive care environment is extremely relevant, since the rapid individuation of subject prone to infection should involve the aggressive treatment while patients who have mild and indolent disease need to be identified but not over treated. The role of the underlying disease should be considered as dominant and the primary endpoint in VAP management should ideally be prevention. Areas timely for developing research are strategy for VAP prevention, individuation of biomarkers for early diagnosis and subgroups identification, methods to develop and validate multi-drug resistant pathogens detection on bronchoalveolar lavage (BAL) or serum. We will expose the relevant result of recent clinical translational works that aim to identify novel pathways in VAP diagnosis and treatment.

**Biomarkers for VAP diagnosis**

As already said, clinical criteria for VAP diagnosis present high sensibility but low specificity. Comorbidities and other concomitant conditions as leukocytosis may influence the evaluation of clinical data; fever in ICU patients is extremely common and radiologic criteria is often misleading. The Clinical Pulmonary Infection Score (CPIS) takes into account some easily available parameters: fever, leukocytosis, tracheal aspirates, oxygenation, radiographic infiltrates, and may increase the specificity of diagnosis when the sum of individual scores is higher than 6. The initial data, published by Plugin et al. [8] were not confirmed later in larger studies and, to increase the CPIS specificity, the semi-quantitative cultures of tracheal aspirates with Gram stain was introduced, still with limited efficacy [9]. The weak point of CPIS is probably the inter-individual variability, since a subjective evaluation is required when we are judging the quality of tracheal secretion (purulent/not purulent) and the presence of infiltrate at chest ray.

Since clinical criteria are not specific enough, the need for a simple clinical tool for the diagnosis of VAP is evident. A perfect biomarker (not expensive, not invasive, which helps to avoid excess antibiotic use and assist in the conduct of clinical research) is still lacking, but various biological elements have been proposed, among which Procalcitonin, Pentraxin3, and Soluble Triggering Expressed on Myeloid Cells Type 1 are the most cited in the literature.

Procalcitonin (PTC) is a pro-hormone, precursor of Calcitonin. PTC is synthesized in virtually all organs and in macrophages in response to pro-inflammatory stimuli, particularly stimuli of bacterial origin. In a metanalysis of 7 studies (373 patients, 434 episodes), Sotillo- Diaz et al. [10] found that high plasma PCT levels were associated to an increased risk of suffering ventilator-associated pneumonia (OR: 8.39; 95% CI: 5.4-12.6). Sensitivity and specificity were 76% (69–82) and 79% respectively. Even if these values are fairly acceptable, we should also consider that the CPIS score in selected population (i.e. brain injury) [11] scores even better: 97% sensitivity and 100% specificity and question the role of PCT as unique screening test for VAP early diagnosis [12].

The diagnosis of VAP is not the only field of application of PTC: it could be used for prognosis and to follow antibiotic therapy. Using the combination of PCT plus CPIS may be more powerful than PTC by itself: Su et al. [13] in 2012 demonstrated that procalcitonin levels plus the CPIS score was reliable for prognostic assessment (28-day survival), in sepsis patient with VAP.

Assuming the patients meet the clinical criteria for VAP, the PTC level could guide the duration of antibiotic therapy, allowing a safe individualised strategy for VAP. Pugh et al. [14] reviewed three RCTs which investigated strategies to reduce antibiotic exposure on the basis of procalcitonin: the experimental strategy advocated discontinuing antibiotic exposure when the serum PTC level was below a cut-off value (0.5 or 0.25 μg/L, depending on the investigators) or fell to less than 20% of the level on Day 0. Duration of antibiotic therapy was significantly shorter in patients treated according to PTC-guided strategy than for patients allocated to standard therapy (durations of therapy for the procalcitonin groups 8.9 days and 11.4 days).

Taking the data all together, PTC looks useful but not unequivocal as a biomarker for VAP diagnosis. The explanation could be that PTC is a part of pro-inflammatory response of the immune system and it could be seen as an assistant to host, in recognition of invasion by bacteria, discriminating viral from bacterial infections. Nevertheless
this hypothesis is just speculative and we need to understand how PTC really “works” during VAP.

Pentatratxin 3 (PTX3) is a protein targeted to inflammation and has been proposed as an alternative biomarker for VAP diagnosis. PTX3 is a member of the long pentraxin subfamily while the C-reactive protein (CRP) is the prototype of short pentraxin and has been widely used, with limited diagnostic and prognostic specificity in infectious diseases.

PTX3 is released by mononuclear phagocytes, neutrophils, epithelial and endothelial cells in response to inflammatory signals; PTX3 recognizes microbial molecules, activates the classical pathway of complement and facilitates recognition by macrophages and dendritic cells. Lin et al. [15] performed the measurement of PTX3 and CRP levels in plasma from 136 consecutive patients receiving mechanical ventilation > 48 hours in a prospective single centre study. PTX3 > 16.43 ng/ml showed specificity of 74.0% and sensitivity of 68.6%, not superior to CRP as a biomarker to diagnose VAP. The authors admit some limitations of this single centre study and propose a larger trial, which at the moment is lacking. Nevertheless, PTX3 is not a specific marker for bacterial infection. Elevated plasma PTX3 concentrations are seen in various inflammatory conditions, which can be concomitant to VAP diagnosis, making PTX3 a marker not enough specific for this complication.

Triggering receptor expressed on myeloid cells-1 (TREM) is a glycoprotein member of the immunoglobulin superfamily. TREM expression is up-regulated in the presence of extracellular bacteria and fungi and some inflammatory conditions. In response to infection, soluble TREM-1 (sTREM-1) can then be measured in body fluids, while sTREM-1 levels are not detectable at baseline in normal individuals.

In Palazzo et al. paper, sTREM-1 levels did not discriminate VAP when compared to quantitative cultures of bronchoalveolar lavage (commonly used as the gold standard) [16]. Using a cutoff value of 204 pg/mL for BALF sTREM-1 levels resulted in sensitivity of 79% and specificity of 23%.

In conclusion, up to now no biomarker has yet improved our clinical capacity to diagnose VAP: biologic markers have been suggested to improve recognition of patients with true infection and facilitate decisions of whether or not to treat. Unfortunately, neither PCT, PTX3 or sTREM-1 fulfill all expectations.

In the recent years, it is been recognized that the multivariate model is more promising than a single biomarker for risk assessment of disease. This multibiomarker approach has progressed by recent advances in clinical proteomics. Proteomics is a branch of biotechnology concerned with applying the techniques of molecular biology, biochemistry, and genetics to analyzing the structure, function, and interactions of the proteins produced by the genes of a particular cell, tissue, or organism, with organizing the information in databases, and with applications of the data (as in medicine or biology) [17]. In 2008 Lu et al. published the first global description of the BAL proteome from patients with VAP: they identified 206 proteins, defining the global proteome map of BAL. Four selected proteins (gelsolin, serum amyloid P-component, vitamin D-binding protein and pyruvate kinase) [18] were significantly higher in BAL from patients with VAP (p < 0.05). Applying a modern proteomic approach Nguyen et al. [19] identified a proteomic “signature” that discriminated VAP(+) from VAP(−) patients in Acute Lung Injury patients: it is constituted by three BAL proteins: S100A8, lactotransferrin (LTF), and actin 1 (ACTN1).

The proteomic approach needs computational analyses to become really powerful and study the proteome during VAP. This integrative methodology is a strategy to differentiate clinically relevant subsets of patients.

Metabolomics is the quantitative analysis of a large number of low molecular mass metabolite, substrates or products in metabolic pathways. It’s important to note that Rogers et al. recently published a metabolomic study in critically ill patients [20]: they formed a metabolomic network of 7 metabolites associated with death (gamma-glutamylphenylalanine, gamma-glutamyltyrosine, 1-arachidonoylglycerophospholipid (20:4), taurine, succinate, kynurenine). This network achieved a 91% AUC predicting 28-day mortality. Similar studies are still lacking in the field of VAP but would be a very practical and interesting translational approach application.

Prompt identification of VAP caused by MDR bacteria

Once the clinical suspicion of VAP is consolidated, selection of the appropriate antimicrobial therapy is the most urgent and following step. Quantitative culture of bronchoalveolar lavage (BAL) has the highest sensitivity and specificity to diagnose VAP and differentiate true infection from colonisation or inflammation. The CDC recommends that quantitative cultures be performed on these specimens, using ≥ 10⁴ CFU/ml to designate a positive culture (Table 1). Bronchoscopy - necessary to perform BAL- is invasive and requires specialised skills. All culture-based methods may require up to 48 hours for microbial identification: while waiting for microbiology results a broad spectrum antibiotic therapy has to be started. Causative agent may be the most various: Staphylococcus aureus, Pseudomonas aeruginosa and Enterobacteriaceae represent the most frequent pathogens in VAP [21,22]. As a result of the overuse of broad-spectrum antimicrobials such as the carbapenems, strains of Acinetobacter, Enterobacteriaceae, and Pseudomonas...
therapy on days 3

treat microorganism, the physician could switch to mono-
and microbiologic data do not point to a very difficult-to-
apy was appropriate, the clinical course appears favourable,
properties of the agent selected. Provided that initial ther-
c onsideration the pharmacokinetic and pharmacodynamic
ated (to reduce the antimicrobial pressure) is evidently
in A. baumannii resistance to carbapenems may be con-
as the most appropriate choice for the treatment, but
antimicrobial agents: carbapenems have been reported
in A. baumannii shows a broad spectrum of resistance to
disinfection and to persist in the hospital environment.
capacity of bacteria to survive in dry environments and
Transmission of A. baumannii in association with contam-
comial infection, among which is included VAP [24].
Gram-negative cocco-bacillus, responsible of serious noso-
dis of VAP caused by Acinetobacter baumannii, a resilient
Gram-negative cocco-bacillus, responsible of serious noso-
mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, criteria 1 or 2 is met (*or equivalent semi-quantitative result).

| Table 1 CDC Algorithm for VAP diagnosis [1] |
|-------------------------------------------|
| 1= Purulent respiratory secretions AND one of the following: |
| • Positive culture of endotracheal aspirate, ≥ 10^5 CFU/ml * |
| • Positive culture of bronchoalveolar lavage, ≥ 10^5 CFU/ml* |
| • Positive culture of lung tissue, ≥ 10^5 CFU/ml* |
| • Positive culture of protected specimen brush, ≥ 10^3 CFU/ml* |
| 2= One of the following (without requirement for purulent respiratory secretions): |
| • Positive pleural fluid culture |
| • Positive lung histopathology |
| • Positive diagnostic test for Legionella spp. |
| • Positive diagnostic test on respiratory secretions for influenza virus, respiratory syncytial virus, adenovirus, parainfluenza virus |

*aeruginosa susceptible only to polymyxins and tigecycline
have emerged as important causes of VAP [23]. Definition
of VAP implies that the patient has been intubated (or has a
traceostomy) for more than 48 hours. A further differenti-
ation can be made, considering the time of onset:
within 96 hours from intubation (early onset VAP) or after
96 hours of intubation (late onset VAP). This differenti-
ation is important to discriminate the potential causative
pathogens, since the late onset VAP is very frequently due
to multi-drug resistant (MDR) agents. The clinician will
start therapy using broad-spectrum antibiotics and stop it
if the diagnosis of infection becomes unlikely. The need to
accurately diagnose VAP so that appropriate discontinu-
ation or de-escalation of antimicrobial therapy can be initi-
ated (to reduce the antimicrobial pressure) is evidently
essential. The second step is then using narrower spectrum
antibiotics, once the etiologic agent is identified, taking into
consideration the pharmacokinetic and pharmacodynamic
properties of the agent selected. Provided that initial ther-
apy was appropriate, the clinical course appears favourable,
and microbiologic data do not point to a very difficult-to-
treat microorganism, the physician could switch to mono-
therapy on days 3–5. But, what if the initial therapy is not
appropriate or if a therapy is started but is inefficacious
against drug resistant bacteria?

A clear example comes from the difficult management
of VAP caused by Acinetobacter baumannii, a resilient
Gram-negative cocco-bacillus, responsible of serious noso-
comial infection, among which is included VAP [24].
Transmission of A. baumannii in association with contam-
ination of hospital equipment or cross-transmission among
patients is easy and common. This spread is linked to the
capacity of bacteria to survive in dry environments and
their need for simple growth conditions and to withstand
disinfection and to persist in the hospital environment.
A. baumannii shows a broad spectrum of resistance to
antimicrobial agents: carbapenems have been reported
as the most appropriate choice for the treatment, but
in A. baumannii resistance to carbapenems may be con-
firmed by some carbapenemases (metalloenzymes) that
hydrolyze imipenem and meropenem. In case of CRAB
(carbapenem-resistant A. baumannii), colistin is the drug
of choice to cure the infection even if it has severe
collateral effects and a large rate of failures [25]. Then,
A. Baumannii infections need to be rapidly identified, in
order to treat the pathogen and cure the patients but
also limit the spread, which can cause a micro-epidemic
within the ICU. Nevertheless, resistant A. baumannii
needs to be promptly isolated and the resistant strains
have to be identified to allow the use of colistin or com-
bination of drugs since the first day of VAP diagnosis,
not waiting for the time (3–4 days, depending on the in-
sitution) necessary for obtaining the results of culture
and sensitivity. The importance to start the correct regi-
men immediately is evident in a serious and potentially
epidemic disease as VAP caused by MDR organism but
the clinical routine has not yet the tools to get simplifica-
tion of the causative diagnosis. Promising new techniques
and the application of translational methods to daily
practice may overcome some difficulties. Real-time PCR,
hybridization and mass spectrometry-based platforms are
methods providing quantitative results, which can sup-
port organism identification and detect bacterial resist-
ance directly from clinical specimens [26].

Quantitative polymerase chain reaction (qPCR) i.e.
may reduce the time for microbiological diagnosis,
allowing to start immediately the right antibiotics and
avoiding unnecessary overtreatment. Kwon et al. tried
qPCR for etiologic diagnosis of Methicillin-Resistant
Staphylococcus aureus (MRSA) pneumonia on bronchoal-
veolar lavage or bronchial washing samples [27]. Molecular
identification of MRSA was based on the presence of the
mecA and femA-SA gene, with the absence of the femA-
SE gene. The sensitivity and specificity of this assay were
88.9% and 88.9% respectively (compared with quantitative
cultures). Applying this assay to BAL analysis certainly
improves the diagnosis but it does not avoid the use of
invasive technique as bronchoscopy. To identify pattern-
derived volatile biomarkers in breath would be a non-
invasive method to diagnose VAP. Filipiak et al. made in vitro
experiments with Staphylococcus aureus and Pseudo-
monas aeruginosa (bacteria most frequently found in VAP
patients) to investigate the release or consumption of
volatile organic compounds by gas chromatography mass
spectrometry (GC-MS). The Authors concluded that: “the detection and perhaps even identification of bacteria could be achieved by determination of characteristic volatile metabolites, supporting the clinical use of breath-gas analysis as a non-invasive method for early detection of bacterial lung infections” [28]. Chromatography for microbiological definition appears as a very interesting application of a translational technique to VAP microbiological diagnosis.

Pathogenesis of VAP and its prevention in a genomic perspective

The relevance of VAP pushed the development of a national programme in the USA to reduce its incidence.

Figure 1 From Mortensen [29] with permission: summary of the dynamic interplay between A. baumannii and the host. (1) A. baumannii can adhere and invade host cells, leading to stimulation of the pro-inflammatory immune response. (2) The inflammatory response is initiated by TLR4 recognition of LPS which then activates MAPK and NF-κB pathways. TLR2 is also reported to detect A. baumannii. (3) Activation of these receptor proteins leads to subsequent transcription and secretion of pro-inflammatory mediators such as cytokines IL-6 and TNF-α and chemokines KC/IL-8 and MIP-2. (4) These chemokines recruit granulocytes and lymphocytes that are required for controlling infection. (5) Following A. baumannii infection host cells also undergo apoptosis. (6) Other host defences include nutritional immunity, ROS/RNS production, and antimicrobial peptides. (7) In response to the host environment, A. baumannii expresses several virulence factors implicated in pathogenesis, which are displayed in the inset of the figure. The illustration depicts those proteins and molecules that are functionally characterized and those that are predicted to be expressed. The question marks designate areas in which there are significant gaps in our knowledge.
[5]. Many efforts have been proved inefficacious or controversial (e.g., selective digestive decontamination) till now. Nevertheless, counteracting the pathogenetic pathways and limiting the risk factors sounds a reasonable option. The first measure to reduce VAP is to limit exposure to mechanical ventilation by preferring non-mechanical ventilation when possible and limiting its duration. Other prevention practices aim at reducing airways colonisation (such as hygiene before manipulating airways and oral care decontamination using chlorhexidine), or preventing aspiration (e.g., by nursing in the semirecumbent position, or maintaining a sufficient cuff pressure).

Colonisation of the upper airways is probably the main risk factor for VAP: it is extremely frequent and rapidly acquired in ICU but not all the colonised patients develop any clinical significant infection, neither all the tracheobronchitis (VAT) become VAP. Normally, bacterial pathogen-associated molecular patterns (PAMPs) are detected by innate immune receptors on host cells, whose intracellular signalling pathways promote transcription, processing and secretion of inflammatory mediators [29]. The immune response is principally dependent on how the host interacts with a given pathogen (Figure 1).

Martin Loaches et al. compared VAP/VAT gene expression using genome-wide oligonucleotide microarrays [7]. Comparison of gene expression profiles in the pre-infection period revealed 5595 genes expressed differentially between VAP and VAT. The Authors reported that patients who developed VAP had immune impairment in the pre-infection period, with a lower expression of genes involved in the complement system, compared to patients developing simple tracheobronchitis.

Swanson et al. in 10 trauma patients that later developed VAP, found that gene expression profiles of lipopolysaccharide stimulated blood cells were different from those expressed in controls who did not develop VAP and showed 5 genes (PIK3R3, ATP2A1, PI3, ADAM8, and HCN4) common to all significant gene sets used in the cross validation tests [30]. After LPS stimulation of whole blood, the expression of these five genes was down

![Figure 2 From Swanson with permission: hierarchical clustering of VAP − and VAP + patients. (A) Hierarchical clustering of 810 differentially expressed genes in patients that went on to develop ventilator-associated pneumonia (blue) and those that did not (red). (B) Hierarchical clustering with the five genes that were common to all sets used in the cross validation tests.](image-url)
regulated in patients who later suffered from VAP. Hierarchical clustering using these five genes accurately categorized 95% of patients and PCA visualization demonstrated two discernable groups, VAP + and VAP − (Figure 2). Of the five genes identified, three appear to have a role in host response to infection while HCN4 and ATP2A1 are not directly linked with infection. The environment of the immune-compromised host and the contribution of the anti-inflammatory response to controlling damaging inflammation have important implications to the pathogenesis that we are beginning to appreciate. Immunomodulatory therapeutics in these patients with compromised immune status may be a beneficial strategy for treatment of nosocomial infections.

**Review and conclusion**

Ventilator Associated Pneumonia (VAP) is one of the most common nosocomial infections in ICU presenting with not specific symptoms and clinical signs. Too many VAP patients still receive inadequate initial antibiotics even if it is well known that the incidence of MDR pathogen infections is on the rise in ICU. VAP is one of the major sites for emergence of MDR pathogens because subtherapeutic antibiotic concentrations in the lung necessitate longer duration of therapy, thereby favoring selection of resistant bacteria. The choice of the initial empiric antibiotic is challenging; the administration of “broad spectrum” antibiotics may be the safest decision but is associated to increased resistance rate and failure of therapy. Combined antibiotics regimens or more risky antibiotics as colistin may be the only available choice i.e. when MDR *Acinetobacter* spp. is suspected. The most practical solution, at the moment, seems to reduce the time of empiric therapy at its minimum, starting as soon as possible a short course of focused antibiotics. A short course of antibiotic treatment (7–8 days) is effective at successfully clearing the infection, reducing the duration of antibiotic administration,
and decreasing antibiotic resistance without affecting in-
hospital mortality, ventilator days, or hospital length of
stay when compared with a 10-day to 15-day course but
currently, there is not enough data to support further
shortening the duration of antibiotic treatment in pa-
ients with culture proven VAP.

Although our insight has significantly increased over
the past years, a translational approach, with application
of genomics, proteomics and metabolomics methodolo-
gies to this severe clinical problem is required to better
understand the disease and hypothesize new therapeutic
strategies. Translational approach seems to be able to
boost the necessary knowledge of VAP in several ways
(Figure 3). The vast number of measurements that could
becomes available for VAP will require powerful informa-
tics methods for organizing the data. We should look
for deeper interactions among basic science researchers
and clinicians to push on translational approach even in
the newest fields as nutribolomics, which could provide
new insight and possibility for the cure of VAP.

Competing interest

The authors declare that they have no competing interests.

Authors’ contributions

OP conceived of the study, and drafted the manuscript. XW conceived of
the study and helped to draft the manuscript. Both authors read and
approved the final manuscript.

Author details

1 Università di Salerno, Baronissi (SA), Italy. 2 Fudan University, Shanghai, China.
3 Zhongshan Hospital, Fudan University, Shanghai, China.

Received: 22 May 2014 Accepted: 14 July 2014
Published: 28 July 2014

References

1. Centers for Disease Control and Prevention: Ventilator-Associated Event
(VAE). 2014, 1, 101–46. http://www.cdc.gov/hhsr/pdfs/pscManual/10-
VAE_FINAL.pdf

2. Di Bonito M, Caliazo S, Iannazzone M, Miccichi V, De Marco G, De
Roberts E, Tufano R, Piazza O: Prognostic differences between VAP
from acinetobacter baumannii and VAP from other microorganisms.
Trans Med Unit 2012, 3:15–21.

3. Klein Klouwenberg PM, van Mourik MS, Onkodes DS, Horn J, Schultz MJ,
Cremer CL, Bonten MJ, on behalf of the MARS consortium: Electronic
implementation of a novel surveillance paradigm for ventilator-
associated events: feasibility and validation. Am J Respir Crit Care
Med 2014, 189(9):947–955.

4. Rosenberger LH, Hranecek T, McLeod MD, Pollitano AD, Guidry CA, Davies S,
Sawyer RG: Improvements in pulmonary and general critical care reduces
mortality following ventilator-associated pneumonia. J Trauma Acute
Care Surg 2013, 74(2):354–360.

5. Croce MA, Brasel KJ, Coimbra R, Adams CA Jr, Miller PR, Pasquale MD,
McDonald CW, Vuthipadadon S, Fabian TC, Tollef EA: National trauma
institutes prospective evaluation of the ventilator bundle in trauma
patients: does it really work? J Trauma Acute Care Surg 2013, 74(2):568–574.

6. Piskin N, Aydemir H, Ozturkay N, Akduman D, Comert F, Koturk F, Celebi G:
Inadequate treatment of ventilator-associated and hospital-acquired
pneumonia: risk factors and impact on outcomes. BMC Infect Dis 2012,
12:268.

7. Martin-Looches I, Papiol E, Almansa R, Lopez-Campos G, Bermejo-Martín JF,
Rello J: Intubated patients developing tracheobronchitis or pneumonia
have distinctive complement system gene expression signatures in the
pre-infection period: a pilot study. Med Intensiva 2012, 36(4):257–263.

8. Pugin J, Auckenthaler R, Milli N, Janssens JP, Lew PD, Suter PM: Diagnosis of
ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic
and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir
Dis 1991, 143(5 Pt 1):1121–1125.

9. Zilberberg MD, Shorr AF: Ventilator-associated pneumonia: the clinical
pulmonary infection score as a surrogate for diagnostics and outcome.
Clin Infect Dis 2010, 51(Suppl 1):S131–S135.

10. Sotillo-Díaz JC, Bermejo-López E, Garcia-Olivares P, Penal-Gutierrez JA,
Sancho-González M, Guerrero-San JE: Role of plasma procalcitonin in
the diagnosis of ventilator-associated pneumonia. Systematic review and
metaanalysis. Med Intensiva 2014, 38(6):337–346.

11. Pelosi P, Barassi A, Severgnini P, Gomiero B, Finazzi G, Ettl GM, Chiaroni M,
Niedermaier MS: Prognostic role of clinical and laboratory
criteria to identify early ventilator-associated pneumonia in brain injury.
Chest 2008, 134(1):101–108.

12. Zielinska-Borkowska U, Sireckie T, Zlotowiczcz M, Czarnocka B: Procalcitonin
in early onset ventilator-associated pneumonia. J Hosp Infect 2012,
81(2):92–97.

13. Su LX, Meng K, Zhang X, Wang HJ, Yan P, Jia YH, Feng D, Xie LX: Diagnosing
ventilator-associated pneumonia in critically ill patients with
sepsis. Am J Crit Care 2012, 21(6):e110–e119.

14. Pugh R, Grant C, Cooke RP, Dempsey DJ: Short-course versus prolonged-
course antibiotic therapy for hospital-acquired pneumonia in critically
ill adults. Cochrane Database Syst Rev 2011, 10:CD007577.

15. Lin Q, Fu F, Shen L, Zhu B: Pentraxin 3 in the assessment of
ventilator-associated pneumonia: an early marker of severity. Heart Lung
2013, 42(2):139–145.

16. Piazza SJ, Simpson TA, Simmons JM, Schnapp LM: Soluble triggering
receptor expressed on myeloid cells-1 (STREM-1) as a diagnostic marker
of ventilator-associated pneumonia. Respir Care 2013, 57(12):2052–2058.

17. Anderson NL, Anderson NG: Proteome and proteomics: new
technologies, new concepts, and new words. Electrophoresis 1998,
19(11):1853–1861.

18. Lu YT, Han CL, Wu CL, Yu TM, Chien CW, Liu CL, Chen YJ: Proteomic
profiles of bronchoalveolar lavage fluid from patients with ventilator-
associated pneumonia by gel-assisted digestion and 2-D-LC/MS/MS.
Proteomics Clin Appl 2008, 2(8):1208–1222.

19. Nguyen EV, Gharib SA, Piazza SJ, Chow YH, Goodlett DR: Schnapp
LMProteomic profiling of bronchoalveolar lavage fluid in critically ill
patients with ventilator-associated pneumonia. PLoS One 2013,
8(3):e58782. doi:10.1371/journal.pone.0058782.

20. Rodgers AJ, McGeachie M, Baron RM, Gazoulian J, Haspel JA, Nakahira K,
Friedenburgh LE, Hunninghake GM, Raby BA, Matthey MA, Otero RM,
Fowler VG, Rivers EP, Woods CW, Pandes G, Langley RI, Choi AM: Metabolic
derangements are associated with mortality in critically ill adult patients.
PloS One 2014, 9(1):e87538.

21. Bariber F, Andremont A, Wolff M, Bousadma L: Hospital-acquired pneumonia
and ventilator-associated pneumonia: recent advances in epidemiology and
management. Curr Opin Pulm Med 2013, 19(2):216–228.

22. Gatalid M, Sbendando V, Leo A, Piazza D: Biofilm-dependent airway
infections: a role for ambroxol? Pulm Pharmacol Ther 2014,
28(2):98–108.

23. Lambiase A, Rossano F, Tafuro M, Tafuro T, Katia MR, Tafuro T: Typeing of pseudomonas aeruginosa isolated from patients with VAP in
an intensive care unit. New Microbiol 2009, 32(3):277–283.

24. Lambiase A, Piazza O, Rossano F, Del Pezzo M, Tafuro R, Katia MR, Tafuro T, Katia MR, Tafuro T: Persistence of carbapenem-resistant acinetobacter baumannii
strains in an Italian intensive care unit during a forty-six month study
period. New Microbiol 2012, 35(2):199–206.

25. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, Koturk F,
Örnek T, Celebi G: Colistin vs. the combination of colistin and rifampicin
for the treatment of carbapenem-resistant acinetobacter baumannii
ventilator-associated pneumonia. Epidemiol Infect 2013, 141(10):1214–1222.

26. Lung M, Codina G: Molecular diagnosis in HAP/VAP. Curr Opin Crit Care
2012, 18(5):477–484.

27. Kwon SJ, Jeon T, Lee D, Na M, Choi EG, Son JW, Yoo EH, Park CG, Lee HY,
Kim JO, Kim SY, Kang J: Quantitative PCR for etiologic diagnosis of
meticillin-resistant staphylococcus aureus pneumonia in intensive care
unit. Tuberc Respir Dis (Seoul) 2012, 72(3):293–301.
28. Filipiak W, Sponring A, Baur MM, Filipiak A, Ager C, Wesenhofer H, Nagl M, Troppmair J, Aman A: Molecular analysis of volatile metabolites released specifically by staphylococcus aureus and pseudomonas aeruginosa. *BMC Microbiol* 2012, 12:113.

29. Mortensen BL, Skaar EP: Host-microbe interactions that shape the pathogenesis of acinetobacter baumannii infection. *Cell Microbiol* 2012, 14(9):1336–1344.

30. Swanson JM, Wood GC, Xu L, Tang LE, Medbohm B, Homayouni R, Croce MA, Fabian TC: Developing a gene expression model for predicting ventilator-associated pneumonia in trauma patients: a pilot study. *PLoS One* 2012, 7(8):e42065.

doi:10.1186/2001-1326-3-26

Cite this article as: Piazza and Wang: A translational approach to ventilator associated pneumonia. *Clinical and Translational Medicine* 2014 3:26.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com